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Introduction
Acute cholecystitis consists of various morbid condi-
tions, ranging from mild cases that are relieved by 
the oral administration of antimicrobial drugs or that 
resolve even without antimicrobials to severe cases 
complicated by biliary peritonitis, each of which re-
quires a different treatment strategy. Decisions on an-
timicrobial therapy must be based upon knowledge of 
the likely infecting microorganisms, the pharmacokinet-
ics/pharmacodynamics and adverse reactions/effects of 
available agents, and the results of local antimicrobial 
susceptibility testing (local antibiogram). The severity 
of illness and history of exposure to antimicrobials are 
also key factors in determining appropriate therapy. 
Once presumptive antimicrobial agents are selected and 
administered, they should be changed for more appro-
priate agents, based on the organisms identiﬁ  ed and 
their susceptibility testing results. Continuous use of 
unnecessarily broader-spectrum agents should be avoid-
ed to prevent the emergence of antimicrobial resistance. 
Furthermore, the duration of therapy should be strictly 
evaluated periodically to avoid unnecessarily prolonged 
use of antimicrobial agents.
In this article we discuss the medical treatment stra-
tegy, including antimicrobial therapy, for acute chole-
cystitis. In an extensive literature search, we were 
faced with the fact that there were very few, if any, 
randomized controlled trials (RCTs) of antimicrobial 
therapy for acute cholecystitis. Therefore, we propose 
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consensus-based and in vitro activities-based guidelines 
for empirical antimicrobial therapy for acute cholecys-
titis. The text is organized in a question and recommen-
dation format.
Q1.  What microbiological studies should be performed 
in acute cholecystitis?
Patients with mild case of disease, with little abdominal 
pain and mild inﬂ  ammatory ﬁ  ndings, (closely mimick-
ing biliary colic), may be observed and treated with oral 
antimicrobial drugs or even observed without anti-
microbials. In these patients, the administration of 
nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) is 
recommended, as described below.
When early cholecystectomy is performed, antimicro-
bial therapy may be considered prophylactic in that the 
infection itself is surgically removed.
Q3.  Is the administration of NSAIDs to patients 
suffering from an attack of biliary colic effective to 
prevent the development of acute cholecystitis?
Table 1.  Bacterial culture positive rates in bile (%) in various biliary diseases
          Choledo-
    Non-biliary Chole-  Acute  cholithiasis  Hepatolithiasis
  Bile disease  lithiasis  cholecystitis  (+cholangitis) (+cholangitis)
Chang (2002)3  Gallbladder   17.0  47.0  63.0  70.0
Csendes (1996)4, 5  Gallbladder 0  22.2  46.1
Csendes (1994)6  Gallbladder 0  32.0  41.0  58.0
Maluenda (1989)2  Gallbladder 0    43.0
Csendes (1975)7  (Gallbladder wall)      47.0 (Chronic; 33)
Kune (1974)8  Gallbladder 0  13.0  54.0  59.0
Bile and blood culture should be performed at all 
available opportunities, especially in severe cases 
(recommendation B).
The clinical signiﬁ  cance of microbial examination in 
acute cholecystitis depends on the severity of the dis-
ease. Although most mild and moderate cases are cur-
able without microbial information, biliary infection is 
associated with postoperative complications and higher 
mortality rates in patients with severe cases or biliary 
stones. A positive bile culture is correlated with the 
progression of the cholecystitis to a severe form (level 
2b–3b).1,2  Therefore, especially in severe cases, gall-
bladder bile should be collected at the time of operative, 
laparoscopic, or percutaneous intervention for culture 
and susceptibility testing. A sample of the gallbladder 
wall should be sent separately for culture, and for his-
topathology if needed. Aerobic cultures only should 
be obtained. Positive rates for bacterial culture in 
acute cholecystitis and other biliary diseases are listed 
in Table 1 (level 2b–3b).3–8
The importance of blood culture results is relatively 
limited in acute cholecystitis and the presence of posi-
tive blood cultures does not alter the agents to be used 
or the duration of treatment.
Q2.  How should antimicrobial agents be used in 
patients with acute cholecystitis?
Antimicrobial agents should be administered to 
patients diagnosed with acute cholecystitis, except 
for those with mild cases (recommendation A).
Administration of NSAIDs to patients with an 
attack of biliary colic is recommended, to prevent 
the onset of acute cholecystitis (recommendation 
A).
NSAIDs such as diclofenac or indomethacin should be 
used in the medical treatment for their analgesic effects 
and their inhibition of prostaglandin release from the 
gallbladder wall. An RCT of NSAID administration 
(75  mg diclofenac; intramuscular injection) in patients 
with biliary colic attack showed that the NSAID had the 
effect of relieving the patients’ pain and preventing the 
progression of the disease to acute cholecystitis (level 
1b).9 Although it has been reported that NSAIDs ef-
fectively improve gallbladder function in patients with 
chronic cholangitis (level 3a),10 there is no report to date 
showing that NSAID administration after the onset of 
acute cholecystitis alleviates the disease.
Q4.  What are the important factors for consideration 
in antimicrobial drug selection?
(1)    Antimicrobial activity against causative 
bacteria
(2)  Severity of acute cholecystitisM. Yoshida et al.: Antimicrobial therapy for acute cholecystitis  85
The dose of antimicrobial agents should be reduced for 
patients with reduced renal function. Because most 
cephalosporins, penicillins, aminoglycosides, and car-
bapenems are excreted by the kidneys, the dose is to be 
reduced for patients with decreased renal function. The 
Sanford guide to antimicrobial therapy  (2006)11  and 
Goodman and Gilman’s The pharmacological basis of 
therapeutics12 recommend that renal function be esti-
mated by the following formula:
Predicted creatinine clearance from serum creatinine 
(×0.85 for females) = (140 − age)(optimum body 
weight kg)/(72 × serum creatinine mg/dl)
where male optimum body weight is 50.0 kg + 0.9 kg/cm 
(150 cm and taller) and female optimum body weight is 
45.5 kg + 0.91 kg/cm (150 cm and taller)
Drug dosage adjustment for ceftriaxone is not necessary 
in patients with renal dysfunction. By contrast, dose 
adjustment of ceftriaxone may be indicated in patients 
with severe hepatic impairment.11
If patients have a biliary obstruction that blocks the 
enterohepatic circulation of bile, in view of the fact that 
the administration of wider-spectrum antimicrobials 
such as third- and fourth-generation cephalosporins 
may replace intestinal microorganisms and disturb vita-
min K absorption, which could lead to hemorrhage, 
vitamin K is administered intravenously as required.
Q5.  Should penetration into the bile or gallbladder 
wall be considered important in the selection of 
therapeutic antimicrobials in acute cholecystitis?
There is a common belief, particularly in Japan, that 
antimicrobial agents with excellent penetration into 
the gallbladder wall should be chosen for antimicrobial 
therapy. There was some debate on whether penetra-
tion into the gallbladder should be considered in choos-
ing antimicrobial agents. However, there are no clinical 
or experimental data to support this. For reference, 
Table 2 shows antimicrobial agents with good penetra-
tion of the gallbladder wall (level 3b–4).13–16
The usefulness of biliary wall penetration for the 
selection of therapeutic antimicrobials in acute 
Table 2.  Intravenous antimicrobial drugs with good penetration into the gallbladder 
wall5
Penicillins Ampicillin,  piperacillin,  piperacillin/tazobactam
Cephalosporins
  1st generation  Cefazoline
  2nd generation  Cefmetazole, ﬂ  omoxef, cefotiam,
  3rd, 4th generation  Cefoperazone/sulbactam,13 ceftriaxone,14 ceftazidime,
    cefpirome, cefozopran
Fluoroquinolones Ciproﬂ  oxacin,13 pazuﬂ  oxacin
Monobactams Aztreonam15
Carbapenems Meropenem,  panipenem/betamipron
Lincosamides Clindamycin16





Fig. 1.  Clinical question, “Should the 
biliary penetration of antimicrobial 
agents be considered important in their 
selection in moderate or severe acute 
cholecystitis?” Responses at the Interna-
tional Consensus Meeting. Responses 
from Japanese panelists and panelists 
from abroad showed that 78% (21/27) 
and 39% (9/23), respectively, answered 
“Yes” to the question
(3)    Presence/absence of renal and hepatic 
dysfunction
(4)    Patient’s past history of antimicrobial 
administration
(5)  Local susceptibility patterns (antibiogram)
Drug dosage should be adjusted in patients with 
decreased renal function. The Sanford guide to 
antimicrobial therapy  and  Goodman and Gil-
man’s the pharmacological basis of therapeutics 
should be consulted (recommendation A).86  M. Yoshida et al.: Antimicrobial therapy for acute cholecystitis
cholecystitis is still controversial. At the Tokyo Inter-
national Consensus Meeting, consensus was not ob-
tained on this question (Fig. 1). See “Discussion” for 
details.
Q6.  What are the results of clinical trials regarding 
antimicrobial therapy for acute cholecystitis?
Three RCTs have evaluated the effect of antimicrobial 
agents in patients with acute cholecystitis (Table 3) 
(level 2b),17–19  and all of them demonstrated that re-
cently developed antimicrobial drugs had effectiveness 
and usefulness equivalent to that of ampicillin and an 
aminoglycoside, which was regarded as a standard 
regimen for cholecystitis in the 1980s (level 4–5).20,21 
Therefore, according to the clinical trials available so 
far, piperacillin, ampicillin and an aminoglycoside, as 
well as several cephalosporins, are recommended for 
the treatment of acute cholecystitis (recommendation 
A).
However, only one RCT focused only on acute chole-
cystitis. In addition, the antimicrobial agents widely used 
at present for acute cholecystitis, including penicillin/
β-lactamase inhibitors, carbapenems, and the third- and 
fourth-generation cephalosporins, were not tested in 
these RCTs. In this regard, in the Tokyo Guidelines, 
we recommend alternative regimens of antimicrobial 
agents, as given below. A consensus on these recom-
mendations was reacted at the International Consensus 
Meeting.
Q7.  What are the current recommendations for 
antimicrobial therapy in acute cholecystitis?
Table 3.  Comparative clinical tests of antimicrobial drugs in cholecystitis
Authors Subjects  Antimicrobial  Clinical  cure  rate  Signiﬁ  cant difference
Muller (1987)17  Cholecystitis ABPC+TOB 11/13  (85%)
    Piperacillin 18/19  (95%)  NS
    Cefoperazone 19/20  (95%)  NS
Chacon (1990)18  Cholecystitis +  Peﬂ  oxacin 49/50  (98%)  NS
    cholangitis ABPC+GM 45/47  (95.7%)
Thompson (1993)19  Cholecystitis +  Cefepime 78/80  (97.5%)  NS
    cholangitis Mezlocillin+GM 40/40  (100%)
ABPC, ampicillin; TOB, tobramycin; GM, gentamicin
<Japanese panelists> < Panelists from abroad >
YES 100% (28/28) YES 87% (20/23)
Fig. 2.  Clinical question: “Should empirically adminis-
tered antimicrobial drugs be changed for more appr-
opriate agents according to the identiﬁ  ed causative 
microorganisms and their sensitivity to antimicrobials?” 
Responses at the International Consensus Meeting. Re-
sponses from Japanese panelists and panelists from abroad 
showed that 100% (28/28) and 39% (20/23), respectively, 
answered “Yes” to the question
•  Antimicrobial drugs should be selected accord-
ing to the severity assessment.
• Empirically administered antimicrobial drugs 
should be changed for more appropriate agents, 
according to the identiﬁ  ed causative microor-
ganisms and their susceptibility testing results.
Antimicrobial drugs should be selected on the basis 
of the severity assessment, according to the Infectious 
Diseases Society of America (IDSA) guidelines (level 
4)22  for complicated intraabdominal infections. But 
there is very little evidence that supports this notion. 
Adequate dosages of antimicrobial drugs should be de-
termined in each country; the issue of cost is not ad-
dressed in the Tokyo Guidelines. See “Discussion at the 
Tokyo International Consensus Meeting” for details.
Empirically administered antimicrobial drugs should 
be changed for more appropriate agents according to 
the identiﬁ  ed causative microorganisms and their sus-
ceptibility testing results. There is very little evidence 
that supports this notion; however, at the Tokyo Inter-
national Consensus Meeting, consensus in support of 
this notion was obtained with Japanese and overseas 
panelists (Fig. 2).
Mild (grade I) acute cholecystitis
Mild (Grade I) acute cholecystitis is often caused by a 
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therefore monotherapy with one of the antimicrobial 
drugs listed in Table 4 is recommended. Because intes-
tinal organisms producing β-lactamase, which are resis-
tant to penicillins, and cefazoline, are likely to be 
detected, the use of penicillin/β-lactamase inhibitors, 
such as piperacillin/tazobactam,23 or ampicillin/sulbacta m 
is recommended.
Patients with mild acute cholecystitis, with relatively 
mild abdominal pain and mild inﬂ  ammatory ﬁ  ndings on 
laboratory data and imaging studies, closely mimicking 
biliary colic, may be observed with oral antimicrobial 
drugs, or even without antimicrobials.
Moderate (grade II) and severe (grade III) acute 
cholecystitis (Table 5)
For moderate (grade II) acute cholecystitis, wider-
spectrum penicillins, second-generation cephalosporins, 
and oxacephems are recommended empirically as the 
drug of ﬁ  rst choice. For patients with severe (grade III) 
acute cholecystitis, who are often infected with multiple 
and/or resistant organisms (level 2b–3b),24–26 third- and 
fourth-generation cephalosporins with a wider antimi-
crobial spectrum are recommended as the drug of ﬁ  rst 
choice. Depending on the local susceptibility patterns 
(antibiogram), if the drug of ﬁ  rst choice is ineffective, 
ﬂ  uoroquinolones and carbapenems can be used.
It should be emphasized that the inappropriate use 
or overuse of third- and fourth-generation cephalospo-
rins and carbapenems would likely result in the emer-
gence of resistant bacteria.
Of note, the ratio of piperacillin to tazobactam in 
Japan (4 : 1) is different vs. from that used in the United 
States (8 : 1).
In each country, antimicrobials should be chosen 
from the available agents that meet the concepts and 
criteria discussed above and agreed on at this Consen-
sus Meeting.
Q8.  What is the appropriate antimicrobial 
dosing regimen?
On the basis of pharmacokinetics and pharmacody-
namics, there is a signiﬁ  cant difference between the 
United States and Japan in antimicrobial dosing regi-
mens. To provide practical recommendations on anti-
microbial therapy, this issue, even though it is a domestic 
one in Japan, needed to be discussed here as well as at 
the Consensus Meeting.
Regarding Japanese domestic issues about antimicro-
bial dosing regimens, the basic principles of antimicro-
bial therapy will be discussed ﬁ  rst.
Antimicrobial therapy is classiﬁ  ed into three types 
according to the purpose of the antimicrobial use. These 
are, presumptive or empirical therapy, deﬁ  nitive or spe-
ciﬁ  c therapy, and prophylaxis. Presumptive therapy is 
the antimicrobial usage when infection is suspected and 
causative organisms are not yet identiﬁ  ed or when the 
results of microbiological studies are pending. After 
the microbiological testing results come back, therapy 
should be changed accordingly, to what is called “deﬁ  ni-
tive therapy or speciﬁ  c therapy.” Lastly, “prophylaxis” 
includes either primary or secondary prevention for 
expected infections in the future. Of note, in our Guide-
lines, presumptive or empirical therapy for biliary tract 
infection is discussed and provided.
After the appropriate antimicrobial agents are 
selected, dosing regimens should be determined, on the 
basis of their pharmacokinetics and pharmacodynamics, 
to achieve the best clinical outcomes and to avoid the 
emergence of antimicrobial resistance. Andes et al.27 
classiﬁ  ed antimicrobial agents by their bactericidal pat-
terns. These are either time-dependent or concentratio n-
dependent. Time-dependent agents are the ones whose 
Table 4.  Antibacterials for mild (grade I) acute cholecystitis
Oral ﬂ  uoroquinolones Levoﬂ  oxacin, ciproﬂ  oxacin
Oral cephalosporins  Cefotiam, cefcapene
First-generation cephalosporins    cefazolin
Wide-spectrum penicillin/  Ampicillin/sulbactam
  β-lactamase inhibitor
Table 5.  Antibacterials for moderate (grade II) and severe (grade III) acute cholecystitis
First options for moderate cases
Wide-spectrum penicillin/β-lactamase Piperacillin/tazobactam,  ampicillin/sulbactam
  inhibitors
Second-generation cephalosporins  Cefmetazole, cefotiam, oxacephem, ﬂ  omoxef
First options for severe cases
Third- and fourth-generation cephalosporins  Cefoperazon/sulbactam, ceftriaxone, ceftazidime, cefepime, cefozopran
Monobactams Aztreonam
One of above + metronidazole (when anaerobic bacteria are detected or are expected to co-exist)
Second options for severe cases
Fluoroquinolones Ciproﬂ  oxacin, levoﬂ  oxacin, pazuﬂ  oxacin + metronidazole (when 
    anaerobic bacteria are detected or are expected to co-exist)
Carbapanems Meropenem,  impenem/cilastatin,  panipenem/betamipron88  M. Yoshida et al.: Antimicrobial therapy for acute cholecystitis
bactericidal activities are affected by the time above the 
minimum inhibitory concentration (time > MIC), i.e., 
the duration of time that bacteria are exposed to an 
antimicrobial concentration above the MIC. For these 
agents, the time intervals of antimicrobial administra-
tion are critical for gaining an appropriate clinical re-
sponse. On the other hand, for concentration-dependent 
agents, the peak concentration at the site of infection is 
important for achieving an appropriate clinical response 
or bactericidal activity. Time-dependent agents include 
β-lactams, and concentration-dependent agents with a 
prolonged persistent effect include ﬂ  uoroquinolones, 
ketolides, and aminoglycosides. Concentration-
dependent agents with a moderate to prolonged 
persistent effect include the macrolides.
In Japan, in general, for most of the available agents, 
signiﬁ  cantly fewer doses per day are approved 
compared with practice in the Unite States. Morever, in 
Japan, the time intervals of administration of time-
dependent agents such as β-lactams do not seem to be 
determined by their half-life.
These facts suggest that, in Japan, antimicrobial 
dosing regimens should be re-considered and/or re-
examined to provide the best available therapy to 
achieve the best clinical outcomes for the patients. To 
provide appropriate dosing regimens, body size differ-
ences among Asians, Caucasians, and other ethnic 
groups should be addressed. At the Consensus Meeting, 
it was agreed that doses per kilogram (body size) should 
be provided, instead of the absolute number of total 
doses of each agent. For details see “Discussion at the 
Tokyo International Consensus Meeting.”
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Discussion at the Tokyo International 
Consensus Meeting
Community-acquired or hospital-acquired 
biliary infections
Henry Pitt (USA): We should talk about community-
acquired or hospital-acquired infections. The bacteriol-
ogy of a de novo cholecystitis/cholangitis patient with 
the latter, most likely to have stones, is one spectrum 
that is typically the E. coli, Klebsiella Enterococcus, En-
terobacter, but it was clear that that subset of patients 
had a different bacteriology with much more resistant 
organisms, more yeast and more methicillin-resistant 
Staphylococcus aureus (MRSA) and the kinds of things 
that are like vancomycin-resistant Enterococcus (VRE) 
now, that are likely to cause trouble. So we have to take 
that into account here as well; that there may be de 
novo cholangitis/cholecystitis, and then there is another 
group of patients that have hospital-acquired type 
infections.
Duration of antimicrobial therapy
Henry Pitt: I think in particular, for the acute cholecys-
titis, if you do a cholecystectomy, that you can often get 
away with a very short course, especially if it is a mild 
case, which meant most of the cases.
Joseph S. Solomkin (USA): The other point I will 
make, just to relay our experience in North America, is 
that there is increasing emphasis on shortened duration 
of therapy and the i.v. to oral switch is very helpful if 
you are interested in sending patients home more 
rapidly; it does reduce, also, the problem of needing to 
have an i.v. in place, and a nurse to give the infusion.
Biliary penetration
At the International Consensus Meeting, 78% (21/27) 
and 39% (9/23), respectively, of the Japanese panelists 
and the panelists from abroad answered “yes” to the 
clinical question: “Should the biliary penetration of 
antimicrobial agents be considered to be important in 
their selection in moderate or severe acute cholecysti-
tis?” (see Fig. 1).
Steven Strasberg (USA): The reason why the im-
portance of biliary penetration in Japan and overseas 
(especially the United States) is signiﬁ  cantly different 
seems to be derived from treatment strategies in both 
countries. In the United States, cholecystectomy tends 
to be performed after diagnosis immediately, so that 
you can often get away with a very short course, and 
biliary penetration is not so important for them.
Nagai (Japan): With acute cholecystitis, the good 
penetration of the antimicrobial selection is nonsense; 
that is what I am telling to my residents.
Drug selection on the basis of severity assessment
Joseph S. Solomkin: The notion that more seriously ill 
patients should get different antibiotics, and that is the 
notion that we put into the IDSA guidelines, and I think 
is suggested here also; one has to realize that there is 
very little real evidence that works. I think it is very 
important to know that there really is very little, if any, 
evidence that that is the case. It is very reasonable to 
simply take an approach that targets the organism sepa-
rate from the severity of illness, and I think that is one 
issue that might be put to this group to respond to 
whether these guidelines should be based on severity 
or not.
Drug dosage and cost
Joseph S. Solomkin: If you are making a recommenda-
tion that these guidelines should include what I would 
call North American dosing; or what would be your 
recommendation? Also, realizing the regulatory issues 
about drug dosing.
Harumi Gomi (Japan): That is the critical point; dos-
ing regimens are the critical point of microbial therapy 
and I personally think that doses should be included in 
the Guidelines. Then for legal issues, I think that this is 
our domestic issue, and we need to ask the government 
or we need to make some actions to make those anti-
microbial agents available for Japanese patients.
Sheung-Tat Fan (China): I wondered if dosage should 
be expressed in terms of the body weight — kilograms 
— rather than absolute amount. I see that there is a 
difference in body size between Asians and Americans, 
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istic; that means we have to talk about the body weight, 
rather than absolute amount.
Harumi Gomi: For example, 30  kg — for these 
low-body-weight patients, we may have to use FDA-
approved pediatric dosage.
Henry Pitt: I think that the issue of cost should be in 
our guidelines as well.
Harumi Gomi: The major reasons for proposals on 
appropriate dosing regimens are as follows:
(a)   Best available medical treatment with appropriate 
antimicrobial dosing regimens should be provided 
to patients, when possibile, to avoid inadequate 
clinical response
(b)   Overuse or unnecessary use of broader-spectrum 
antimicrobial agents, such as carbapenems, should 
be avoided in Japan.
(c)   Medical professionals in Japan should be aware of 
scientiﬁ  cally sound or appropriate antimicrobial 
dosing regimens on the basis of pharmacokinetics 
and pharmacodynamics of the agents
(d)    To make the appropriate dosing regimens available 
in Japan, legal action or policy-making is 
required.